Previous 10 | Next 10 |
NASHVILLE, Tenn., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule fo...
DEER PARK, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Aucta Pharmaceuticals' New Drug Application for ET-105, an innovative form...
DEER PARK, Ill., July 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2019 financial and operating results on Tues...
NASHVILLE, Tenn., July 25, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight ...
Shares of small biotech company Eton Pharmaceuticals (ETON) have risen by roughly 15% since its IPO was priced at $6 in November of last year. The share price was recently knocking at the $9 level, but the company suffered a setback with receipt of a Complete Response Letter from the FDA for...
Gainers: Capricor Therapeutics (NASDAQ: CAPR ) +148% . Carolina Trust BancShares (NASDAQ: CART ) +30% . SSLJ.com Limited (YGTY) +29% . Chicken Soup for the Soul Entertainment (NASDAQ: CSSE ) +22% . AVROBIO (NASDAQ: AVRO ) +22% . Mereo BioPharma Group (NASDAQ: MREO ) +21% . Amer...
Eton Pharmaceuticals (NASDAQ: ETON ) announces that its partner [a subsidiary of Bausch Health Companies (NYSE: BHC ) per a February 19 press release ] received a Complete Response Letter (CRL) from the FDA regarding the partner's marketing application seeking approval for EM-100, an eye ...
DEER PARK, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S Food and Drug Administration (FDA) provided Eton’s partner ...
Eton Pharmaceuticals (NASDAQ: ETON ) inks an agreement with Aucta Pharmaceuticals for U.S. rights to ET-105, an oral liquid formulation of lamotrigine for the adjunctive treatment of partial seizures in epilepsy patients. More news on: Eton Pharmaceuticals, Inc., Healthcare stocks news, ...
Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients NDA was submitted in May 2019; product launch anticipated in 1H 2020 Lamotrigine market currently exceeds $700 million annually DEER PARK, Ill., June 13, 2019 (GLOBE ...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...